Related Experiment Video
Updated: Jun 12, 2026
05:20
Zebrafish Model of Neuroblastoma Metastasis
Published on: March 14, 2021
Advances in Neuroblastoma and Wilms Tumor
1Department of Pediatrics, Division of Hematology, Oncology, Neuro-Oncology, and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, 225 East Chicago Avenue, Box #30, Chicago, IL 60611, USA.
Hematology/Oncology Clinics of North America
|June 10, 2026
Summary
Risk stratification for neuroblastoma and Wilms tumor uses clinical and molecular factors to tailor treatment. This approach improves outcomes by intensifying therapy for high-risk patients and reducing it for low-risk ones.
Area of Science:
- Pediatric Oncology
- Cancer Genomics
- Clinical Risk Stratification
Background:
- Neuroblastoma and Wilms tumor are prevalent pediatric cancers.
- Effective management hinges on accurate risk stratification.
- Current stratification combines clinical and molecular data.
Purpose of the Study:
- To outline the risk stratification methods for neuroblastoma and Wilms tumor.
- To highlight the importance of these factors in treatment decisions.
- To underscore the impact of risk-based management on patient outcomes.
Main Methods:
- Review of established risk stratification criteria for neuroblastoma.
- Analysis of risk stratification factors for Wilms tumor.
- Examination of the role of clinical and molecular markers.
Main Results:
- Neuroblastoma stratification includes age, stage, histology, MYCN status, ploidy, and chromosomal aberrations.
- Wilms tumor stratification involves age, stage, histology, treatment response, and specific genetic markers (LOH, 1q gain).
- Risk stratification guides treatment intensification or minimization.
Conclusions:
- Tailored treatment based on risk stratification improves outcomes for pediatric cancer patients.
- Accurate stratification minimizes overtreatment and its side effects.
- Continued refinement of these factors is crucial for advancing pediatric cancer care.
